within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL04_Orelabrutinib;
model Orelabrutinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EL04;

  annotation(Documentation(
    info ="<html><body><p>Orelabrutinib is an orally administered, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor developed primarily for the treatment of B-cell malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma. It is approved for clinical use in China and is under investigation in other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in adult patients with B-cell malignancies after oral administration.</p><h4>References</h4><ol><li><p>Deng, L, et al., &amp; Zhu, J (2023). Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. <i>American journal of hematology</i> 98(11) 1742â€“1750. DOI:<a href=&quot;https://doi.org/10.1002/ajh.27064&quot;>10.1002/ajh.27064</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37647123/&quot;>https://pubmed.ncbi.nlm.nih.gov/37647123</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Orelabrutinib;
